A Comprehensive Review of Interventional Clinical Trials in Patients with Bone Metastases

Area of Science:

• Oncology
• Cancer Research
• Bone Metastasis Management

Background:

• Bone metastasis significantly worsens prognosis in prostate, breast, thyroid, and lung cancers.
• Over 650 clinical trials have been registered in the past two decades to address bone metastases.
• Effective management of bone metastases is crucial for improving patient outcomes.

Purpose of the Study:

• To comprehensively analyze and regroup interventional clinical trials for bone metastases.
• To discuss various therapeutic strategies and their mechanisms of action.
• To identify potential future strategies for enhancing survival in patients with bone metastases.

Main Methods:

• Systematic review and analysis of interventional clinical trials registered on ClinicalTrials.gov and pharma.id.informa.com.
• Re-grouping of trials based on mechanisms of action, including bone-targeting agents, radiotherapy, small molecule targeted therapy, and combination therapy.
• Discussion of trial data focusing on modifying the bone microenvironment and inhibiting cancer cell growth.

Main Results:

• Identified 554 interventional trials focused on combating bone metastases.
• Categorized trials into bone-targeting agents, radiotherapy, small molecule targeted therapy, combination therapy, and others.
• Highlighted the diverse approaches being investigated to manage bone metastases.

Conclusions:

• Interventional trials for bone metastases employ diverse strategies targeting the bone microenvironment and cancer cell proliferation.
• Further research and strategic development are needed to improve overall and progression-free survival.
• This review provides a framework for understanding the landscape of bone metastasis clinical trials and future directions.